Moleculin Biotech
MBRX
21 hedge funds and large institutions have $8.57M invested in Moleculin Biotech in 2021 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 8 closing their positions.
0% less ownership
Funds ownership: 0.03% → 0.03% (-0%)
22% less capital invested
Capital invested by funds: $10.9M → $8.57M (-$2.36M)
25% less funds holding
Funds holding: 28 → 21 (-7)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
75% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
+$111K |
| 2 |
Charles Schwab
San Francisco,
California
|
+$63K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$24.5K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$17.5K |
| 5 |
MIFH
Migdal Insurance & Financial Holdings
Petach Tikva,
Israel
|
+$7.01K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$140K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$121K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$114K |
| 4 |
Goldman Sachs
New York
|
-$94K |
| 5 |
VF
Virtu Financial
New York
|
-$93K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GCP
26
GSA Capital Partners
London,
United Kingdom
| – | -$114K | -83 | Closed |
|
|
27
Goldman Sachs
New York
| – | -$94K | -69 | Closed |
|
|
VF
28
Virtu Financial
New York
| – | -$93K | -67 | Closed |
|
|
WIC
29
Whitegate Investment Counselors
Concord,
New Hampshire
| – | -$62K | -45 | Closed |
|
|
TRCT
30
Tower Research Capital (TRC)
New York
| – | -$8.17K | -7 | Closed |
|
|
CFO
31
CVA Family Office
Denver,
Colorado
| – | -$2K | -1 | Closed |
|
MBRX Hedge Fund Activity: Q3 2021 in Review
21 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q3 2021, worth a combined $8.57M — down 22% from $10.9M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of MBRX and 2 opened new positions — a net loss of 6 holders — while 6 trimmed existing stakes and 4 added.
The largest buyer was Sio Capital Management, adding an estimated $111K. The largest seller was Citadel Advisors, exiting entirely with an estimated $140K sold.
- 21 institutional investors held Moleculin Biotech (MBRX) as of Q3 2021, down from 28 in Q2 2021.
- Funds reported $8.57M of Moleculin Biotech stock for Q3 2021, down 22% quarter-over-quarter.
- 2 funds opened new Moleculin Biotech positions in Q3 2021 and 8 closed out, a net change of -6 holders.
- The largest Moleculin Biotech buyer in Q3 2021 was Sio Capital Management, an estimated $111K added.
- The largest Moleculin Biotech seller in Q3 2021 was Citadel Advisors, an estimated $140K sold.
Based on aggregated 13F filings for Q3 2021.